Women's HealthApr 30, 2026
The Pap smear has been one of the greatest successes in preventive medicine. Since its introduction in the mid-20th century, countries with organized screening programs have seen cervical cancer mortality drop by as much as 70%.
The test is simple and inexpensive, yet enormously powerful when performed correctly. Despite this success, women often face confusion about when it can or should be scheduled. Menstrual bleeding raises a practical concern, not because it harms the patient, but because it may interfere with the test itself. Understanding the science behind how Pap smears work helps explain why timing matters.
Cancer ScreeningApr 30, 2026
Cologuard detects about 92% of colorectal cancers from a stool sample you collect at home. That's genuinely impressive. But here's the critical distinction most people miss: catching cancer is not the same as preventing it. Colonoscopy can find precancerous polyps and remove them during the same procedure, stopping cancer before it starts. Cologuard can flag some of those polyps but can't do anything about them, and it misses a substantial number of the advanced ones colonoscopy would catch.
Both tests are guideline-endorsed options for average-risk adults. The choice between them isn't about one being "good" and the other "bad." It's about understanding what each test actually does, what it misses, and what happens after you get a result.
Cancer ScreeningApr 30, 2026
The Galleri test screens for signals from over 50 types of cancer using a single blood draw. It works by analyzing cell-free DNA methylation patterns, and the clinical data behind it is both genuinely promising and genuinely limited. The CCGA validation study showed 99.5% specificity and the ability to predict where a cancer signal originates with 88.7% accuracy. But sensitivity for Stage I cancers was just 16.8%, meaning the test misses most cancers at their earliest, most treatable point. If you're considering spending $849 on this test, you deserve a clear picture of what the science actually shows.
Urinary HealthApr 30, 2026
Up to 20% of the general population will, at some point, test positive for occult blood in urine. That is a staggering number for a result that can send you spiraling. The reality: most of these findings are benign. But about 2–5% of adults with confirmed, asymptomatic microscopic hematuria do have a urinary tract malignancy, and others have early kidney disease they don't know about. The challenge isn't the test result itself. It's knowing who needs to act on it and who doesn't.
Occult blood in urine simply means red blood cells are present in amounts too small to see, typically caught on a routine dipstick test. It is not a diagnosis. It is a signal, and signals require context.
Cancer ScreeningApr 30, 2026
Early detection of cancer significantly improves survival rates. The Galleri test requires only a simple blood draw and scans for over 50 types of cancer. Known for its high specificity, the test does, however, have limitations in sensitivity, particularly in the early stages of cancer. Nevertheless, it offers invaluable information into potential cancer threats, especially for those genetically predisposed to the disease.
Blood HealthApr 30, 2026
Eosinophils are small but powerful white blood cells, most famous for their role in allergies and defense against parasites. In recent decades, however, research has uncovered a deeper, more complex role for eosinophils in cancer biology. Elevated eosinophil counts are now being studied as possible signals of underlying malignancies, predictors of treatment response, and even markers of patient survival.
Cancer ScreeningApr 30, 2026
The albumin-to-globulin ratio, often abbreviated as the A/G ratio, is a calculation derived from a standard blood test. It divides the level of albumin, a protein primarily produced by the liver, by the level of globulins, which are a group of proteins with diverse functions including roles in immunity, transport, and clotting. Though the calculation itself is simple, the clinical meaning of an abnormal A/G ratio is complex, weaving together nutrition, inflammation, immunity, and even cancer prognosis.
Cancer ScreeningApr 30, 2026
Most breast MRI BI-RADS scores are not cancer but guide follow-up. BI-RADS 3 and 4A often cause anxiety, but MRI can clarify these findings with high accuracy, helping many avoid unnecessary biopsies.
Body CompositionApr 30, 2026
Dual-energy X-ray absorptiometry, more commonly known as a DEXA scan, is a specialized imaging technique widely used to assess bone mineral density (BMD). It is a non-invasive, low-radiation tool typically employed in diagnosing osteoporosis and evaluating fracture risk. Given its routine use, especially in aging populations and cancer patients undergoing certain therapies, a common question arises: can a DEXA scan detect cancer?
While DEXA scans are not designed to directly identify or diagnose cancer, emerging evidence suggests that under certain circumstances, they may incidentally reveal signs consistent with metastatic disease. This article aims to explain what a DEXA scan is capable of, how it might relate to cancer detection, and what the research says about its diagnostic limitations and possibilities.
Breast MRIApr 29, 2026
MRI offers the highest sensitivity for detecting breast cancer, especially in high-risk women and those with dense breasts. But mammograms and ultrasounds each bring unique advantages. The best imaging plan depends on your personal risk and clinical situation.
Cancer ScreeningApr 29, 2026
Human papillomavirus (HPV) is the central causative agent of cervical cancer and also contributes to other anogenital and head and neck cancers. Traditional methods of detection, such as HPV DNA testing, provide evidence of infection but do not always distinguish between transient infections that may clear spontaneously and those likely to progress toward malignancy. This is where mRNA testing for the viral oncogenes E6 and E7 has emerged as a promising biomarker. Unlike DNA-based methods, E6/E7 mRNA detection reflects the transcriptional activity of high-risk HPV, directly indicating the virus’s oncogenic potential.
Breast MRIApr 28, 2026
Breast MRI is one of the most sensitive tools for detecting cancer in dense or high-risk breasts, but it can feel intimidating if you’ve never had one. This post breaks down exactly what happens during the scan, how to prepare, and tips to make it easier.
Cancer ScreeningApr 28, 2026
The short answer is that a Pap smear can be uncomfortable, and for some women it can cause mild pain. However, the experience is usually brief and manageable and there are effective strategies proven to make the experience less painful. The level of discomfort varies greatly from person to person, depending on factors such as anatomy, age, anxiety, cultural expectations, and the way the procedure is performed.
MammogramApr 28, 2026
Somewhere between 60% and 90% of women report at least some pain or discomfort during breast compression, depending on the study. That number is high, and it deserves an honest answer rather than dismissal. But the intensity and duration matter just as much as the frequency: most women rate the pain as mild to moderate, it resolves within minutes of the plates releasing, and only about 6 to 8% of women in large screening groups report severe pain, defined as a 7 or higher on a 0-to-10 scale.
So the truthful answer is: it will probably hurt some, it probably won't hurt a lot, and it will be over fast.
Cancer ScreeningApr 28, 2026
While colon cancer risk is often seen as age-related, newer research highlights how lifestyle, genetics, and even your body weight can drastically alter your odds. The good news? Many of these risk factors are modifiable.
CancerApr 28, 2026
About 15% of men with a PSA level under 4.0 ng/mL, the traditional "normal" cutoff, have prostate cancer on biopsy. That single finding upended decades of assumptions about what a prostate specific antigen test can and can't tell you.
PSA is one of the most debated blood tests in medicine. Two enormous randomized trials gave seemingly opposite answers about whether screening saves lives. Guidelines have swung from recommending routine testing to advising against it, and back to something in between.
The confusion is understandable. But the research, once you piece it together, tells a more coherent story than the headlines suggest.
Breast CancerApr 28, 2026
Mammography picks up 80 to 90 percent of breast cancers in women without symptoms, and when it catches cancer at stage I, clinical cure rates exceed 90 percent. That's a striking number. But here's the part that surprises most people: once stage I breast cancer is found and treated, piling on extra imaging scans to hunt for spread doesn't improve survival or quality of life. The evidence points to a simple, almost counterintuitive approach after treatment. One yearly mammogram. That's it.
CancerApr 28, 2026
A single blood draw that detected cancer signals across more than 50 tumor types with a false positive rate under 1% sounds like it shouldn't exist yet, but a clinical validation study of over 4,000 participants showed exactly that. The Galleri test, developed by GRAIL, uses DNA methylation patterns in cell-free DNA to find cancer signals that standard screening was never designed to catch.
It's not a replacement for mammograms or colonoscopies. It's aimed at the cancers that have no screening test at all, the ones that tend to show up late and kill quickly.
So what does the science actually support, and where does the test fall short?
Cancer ScreeningApr 28, 2026
Full-body MRI, sometimes marketed as a "preventive" or "executive" health scan, has become one of the hottest trends in proactive health care. The pitch is simple and appealing. But what does the research actually say about whether it is worth it for you?
For the average healthy adult, current evidence does not support routine full-body MRI screening. The scan finds confirmed cancers in only about 1 to 2% of people without symptoms, while triggering uncertain or false-positive findings in roughly a third of everyone scanned. For people with specific high-risk genetic conditions, the picture is very different, and the scan can be genuinely lifesaving.
Prostate CancerApr 28, 2026
Prostate cancer is the most common cancer in men and the second leading cause of cancer death worldwide. Nearly one in six men will face a diagnosis during their lifetime, and in the United States alone, hundreds of thousands of men are diagnosed each year. The disease often develops silently, with no symptoms until it has advanced, which makes screening especially important.
As Prostate Cancer Awareness Month nears its end, it's important to highlight the tests that make the greatest impact on early detection. While most doctors still rely on total PSA, clinical research shows that free PSA delivers stronger predictive value by distinguishing cancer from benign conditions and reducing unnecessary biopsies.
